STOCKS TELEGRAPH

Category: Mid Day Movers

  • Quantum BioPharma (QNTM) Stock Rallies Following Key Business Development

    Quantum BioPharma (QNTM) Stock Rallies Following Key Business Development

    As of the most recent check, shares of Quantum BioPharma Ltd. (NASDAQ: QNTM) were up 14.51% to $6.71, a notable increase on the charts. The recent product launch by its licensee, Celly Nutrition Corporation, is responsible for the notable surge in QNTM stock value. This further solidifies the company’s position in the expanding wellness and healthcare sector.

    Unbuzzd Product Line Expansion

    The creator of the novel beverage “unbuzzd,” Celly Nutrition Corporation, unveiled their new “On-the-Go Powder Stick Packs” in an 8-pack display box. This calculated growth makes it easier to sell unbuzzed in pharmacies, liquor shops, and convenience stores across the US.

    Well-positioned in the projected $2.1 billion worldwide hangover treatment industry, unbuzzd is designed to speed up alcohol metabolism, restore mental clarity, and reduce hangover symptoms. It is anticipated that the new package type would give customers instant accessibility while increasing product awareness and store profitability.

    As of June 30, 2024, Quantum BioPharma still owns 25.71% of Celly Nutrition and enjoys the advantages of a well-structured royalty arrangement. Until total payments exceed $250 million, the corporation will earn a 7% royalty on unbuzzed purchases; after that, royalties will be lowered to 3% in perpetuity. To further broaden its commercial portfolio, QNTM also has the exclusive right to create pharmaceutical or medical versions of comparable items.

    Digital Asset Moves

    In addition to its product efforts, Quantum BioPharma has systematically increased its bitcoin holdings. QNTM now has $3.5 million in cryptocurrency assets after investing an extra $1.5 million in Bitcoin and other digital assets.

    This decision reflects the company’s trust in digital assets as a hedge against currency volatility and a possible source of investment returns, and it is consistent with its goal to use cryptocurrencies for financing and transactions. A completely compliant custodian oversees the management of all bitcoin assets, guaranteeing compliance with audit and financial requirements.

    Recent events demonstrate Quantum BioPharma’s diverse growth strategy, which combines creative product introductions, improved market interaction, and calculated financial diversification to increase long-term shareholder value.

  • Worthington (WOR) Gains Investor Confidence With Impressive Financials

    Worthington (WOR) Gains Investor Confidence With Impressive Financials

    The stock price of Worthington Enterprises, Inc. (NYSE: WOR) saw a sharp increase when the company’s fiscal third-quarter results were announced. WOR shares were trading at $51.27 as of the most recent market check, representing a remarkable 23.11% rise.

    Strong Financials

    According to the company’s most recent earnings report, sales, adjusted EBITDA, and adjusted profits per share (EPS) all increased both sequentially and year over year, indicating strong financial success.

    Worthington Enterprises reported net sales of $304.5 million for the third quarter of fiscal 2025, which is a 3.9% fall from the same period the previous year, or a $12.2 million reduction.

    The deconsolidation of the Sustainable Energy Solutions (SES) sector in the fourth quarter of fiscal 2024 was the main cause of this reduction. Nonetheless, Ragasco’s contributions and higher overall volumes helped to somewhat offset the drop in income.

    Growing Profits and Returns to Shareholders

    Notwithstanding the little decline in sales, the business showed strong profitability. Adjusted EBITDA from continuing operations increased 10% to $73.8 million, while earnings before income taxes increased 30% to $52.6 million.

    In keeping with its shareholder-focused approach, Worthington Enterprises also paid $6.2 million to repurchase 150,000 shares of common stock, which left 5,565,000 shares remaining under the company’s repurchase authorization. Additionally, the business announced that shareholders of record as of June 13, 2025, will receive a quarterly dividend of $0.17 per share on June 27, 2025.

    Financial Stability and Operational Power

    Gains in market share, an improved product mix, and higher gross margins across all of its wholly owned companies propelled Worthington Enterprises’ expansion. In contrast to last year’s strong performance, the ClarkDietrich division showed a reduction in results, while joint ventures were steady.

    These outcomes highlight the business’s capacity to increase operational effectiveness, control expenses, and provide customers with value-added solutions despite macroeconomic uncertainty.

    Moreover, Worthington Enterprises maintained a solid financial position, announcing free cash flow of $44.4 million, up from $40.1 million in the quarter before to this year. With no borrowings under its revolving credit facility and just long-term liabilities, its total debt as of February 28, 2025, was $293.9 million, leaving $500.0 million available for future usage.

  • SurgePays (SURG) Stock Jumps Sharply Following Key Financial Update

    SurgePays (SURG) Stock Jumps Sharply Following Key Financial Update

    According to the most recent market check, shares of SurgePays, Inc. (NASDAQ: SURG) had a sharp increase in trade, rising 51.04% to $2.08. The significant surge follows the company’s disclosure of its financial results, which emphasized excellent future revenue estimates and strategic development efforts.

    Strategic Investments and the Financial Outlook

    In addition to releasing its financial statistics for the fiscal year that concluded on December 31, 2024, SurgePays offered a positive forecast for the upcoming year. Before the end of 2025, the firm expects to have over $200 million in sales and positive operating cash flow.

    The forecast comes after its services in collaboration with AT&T were successfully integrated and formally launched. Revenue and gross profit were significantly impacted by the end of the federally supported Affordable Connectivity Program (ACP) last year.

    In order to overcome these obstacles, the company made calculated investments, such as expanding its point-of-sale (POS) network, integrating with AT&T, and developing its Mobile Virtual Network Enabler (MVNE) platform.

    Wireless Service Expansion

    The nationwide deployment of SurgePays’ retail prepaid cellular brand, LinkUp Mobile, has formally begun. Strong demand from its wide retail distribution network, which includes around 9,000 convenience and community stores, is expected to propel the company’s monthly SIM card shipments to between 250,000 and 300,000.

    In November 2024, SurgePays signed a multi-year strategic deal with AT&T, further consolidating its position in the industry. North America now has complete access to AT&T’s 4G LTE and 5G cellular services thanks to this deal. The complete implementation of the integration as of April 1, 2025, enables the company to improve its service offerings.

    Increasing Market Share

    Additionally, the business has broadened its responsibilities as a Mobile Virtual Network Enabler (MVNE) by offering other telecom operators wireless infrastructure services such SIM provisioning and invoicing. This high-margin revenue stream is expected to scale rapidly in the coming months.

    In reaction to the cessation of ACP financing, SurgePays has successfully retained a percentage of their cellular subscriber base. SURG is well-positioned for one of its most aggressive development stages to date because of a strong infrastructure, a great alliance with AT&T, and a clear route toward revenue growth.

  • OSR Holdings (OSRH) Sees Stock Surge After Positive Trial Results

    OSR Holdings (OSRH) Sees Stock Surge After Positive Trial Results

    Today’s sharp increase in OSR Holdings, Inc. (NASDAQ: OSRH) shares reflects investor confidence following the announcement of encouraging Phase 2a clinical trial findings by the company’s subsidiary, Vaximm AG. OSRH’s stock is up 88.83% as of the most recent session, closing at $3.03 per share.

    Advances in Glioblastoma Treatment

    The innovative biotechnology company Vaximm AG, a part of OSR Holdings, has completed an open-label Phase 2a clinical research assessing the combination of the experimental oral anti-VEGFR-2 vaccine VXM01 with the PD-L1 inhibitor avelumab.

    This trial was conducted on patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer. The study, carried out in collaboration with Merck KGaA in Darmstadt, Germany, produced encouraging results and represented a significant breakthrough in the field of GBM immunotherapy.

    Information on Tolerability and Safety

    Most adverse effects were classified as mild to moderate, and patients generally responded favorably to the combination of avelumab and VXM01. These findings are in line with prior research on the safety of avelumab alone; no new safety concerns were brought up by the combination treatment.

    It’s interesting to note that no significant adverse events (SAEs) were connected to VXM01, and 81.8% of adverse events were related to the disease itself. This shows that the medication has a manageable safety profile in this vulnerable patient group.

    A Positive Clinical Reaction in a Difficult Patient Group

    The VXM01-avelumab combination may offer significant therapeutic improvements for individuals with recurrent GBM, according to the trial’s findings. 4.0% of patients with non-resectable malignancies maintained stable illness, 12.0% showed partial remission, and 12.0% had an objective response.

    Furthermore, regardless of the initial tumor size, responding patients showed a reduction in tumor growth. This implies that a variety of individuals, including those with bigger tumors, may benefit from VXM01.

    Advancing in an Optimistic Manner

    For Vaximm AG and OSR Holdings, the successful conclusion of this Phase 2a study represents an important turning point. Additional research is expected to refine therapy regimens for GBM patients in light of the encouraging safety, tolerability, and early effectiveness evidence.

    OSR Holdings is still dedicated to developing VXM01 as a promising therapeutic option for glioblastoma as well as other illnesses and tumors where its innovative immunotherapy may enhance therapeutic results.

  • VivoPower (VVPR) Shares Surge As Takeover Talks Advance With Energi Holdings

    VivoPower (VVPR) Shares Surge As Takeover Talks Advance With Energi Holdings

    As VivoPower International PLC (NASDAQ: VVPR) moves into advanced talks about a possible purchase, the company’s shares have experienced a notable spike. The value of VVPR stock as of the most recent check was $4.25, representing a remarkable 88.06% rise.

    Negotiations with Energi Holdings

    High-level bilateral talks between VivoPower and Energi Holdings Limited (“Energi”) over an unsolicited, non-binding purchase offer have been confirmed. Energi is a well-known energy solutions company with its headquarters in Abu Dhabi. It was established in 2014 and makes about $1 billion a year.

    VVPR has operations throughout the Middle East, Africa, South Asia, Europe, and Southeast Asia, among other places. Targeting all non-affiliated free float shares of VivoPower at an enterprise valuation of US$120 million, the proposed purchase is set up as an all-cash offer.

    However, due diligence is still required before the acquisition can be finalized. By April 2, 2025, both parties have agreed to complete the pricing, terms, and conditions negotiations. Investors have been reassured by its board that further information would be released when it is ready.

    Spin-Off Strategy for Caret Digital

    VivoPower has also revealed plans to spin out Caret LLC (“Caret Digital”), a subsidiary, through a direct listing on the Nasdaq Stock Market, concurrent with its takeover talks. The company has engaged financial advisors to facilitate the process.

    The decision to pursue a direct listing over a reverse merger is driven by considerations of cost-efficiency and expedited execution. Additionally, this approach enables the seamless distribution of dividend shares to VVPR shareholders while avoiding the regulatory complexities associated with a reverse listing via a non-Nasdaq entity.

    Under the proposed terms, shareholders of VivoPower at a designated future record date will be entitled to receive five (5) shares of Caret Digital for each share of VVPR held, with an implied market capitalization of US$250 million.

    Focus on Cryptocurrency Mining and Bitcoin Optimization

    Caret Digital’s strategic direction will center on cryptocurrency mining, specifically Dogecoin (DOGE). VVPR has outlined plans to leverage DOGE mining economics by converting mined DOGE into Bitcoin (BTC) at a discount.

    This approach aims to optimize BTC yields and enhance overall returns. In order to support its growth trajectory, Caret Digital plans to seek $10 million from strategic investors as part of this strategy.

  • Jayud Global (JYD) Sees Pre-Hour Stock Rally Amid Logistics Growth

    Jayud Global (JYD) Sees Pre-Hour Stock Rally Amid Logistics Growth

    The market is still rising for Jayud Global Logistics Limited (NASDAQ: JYD) after the company announced a major expansion in its logistics offerings. JYD stock was up 9.07% at $5.89 as of the most recent pre-market check. This adds to the gains made during the previous trading session, when shares rose 10.66% to end at $5.40.

    Specialized Air Cargo Service’s First Flight

    Jayud Global successfully began its unique chartered air cargo service between Jakarta, Indonesia, and Fuzhou, China, on March 21, 2025. The sole direct chartered route that connects the two important markets is this recently created air corridor. The service is especially designed to transport goods containing lithium-ion batteries in accordance with International Air Transport Association (IATA) criteria,and is designed to suit unique logistics demands.

    Enhancing the Logistics Infrastructure in Southeast Asia

    A major extension of Jayud Global’s air freight capabilities in Southeast Asia is the launch of the Fuzhou-Jakarta route. The service is especially important for businesses that depend on lithium battery items since it provides a dependable and effective means of delivery to serve the area’s quickly growing e-commerce industry. With its most recent growth, JYDl is well-positioned to take advantage of this growing trend and guarantee smooth cross-border logistics between China and Indonesia.

    Improving Connectivity in E-Commerce and Cross-Border Trade

    Jayud Global improves its capacity for inventory control, warehousing, customs clearance, and procurement by incorporating this unique air route into its current logistical infrastructure. The program is expected to strengthen business links between China and Southeast Asia by drastically cutting delivery times for shipments made via cross-border e-commerce.

    As the need for effective international logistics solutions grows worldwide, Jayud Global’s most recent endeavor exemplifies its dedication to innovation, superior customer service, and market development. JYD’s investment in specialist logistics services strengthens its position as a major participant in the changing global supply chain market.

  • BitFuFu (FUFU) Shares Surge Following Strong Financial Results

    BitFuFu (FUFU) Shares Surge Following Strong Financial Results

    Following the release of its financial results, BitFuFu Inc. (NASDAQ: FUFU) stock price saw a significant rise. As of the last market check, FUFU’s shares were up 23.15% to $5.49. The company’s unaudited financial results for the fiscal year that concluded on December 31, 2024, demonstrated remarkable growth.

    Excellent Development and Strategic Expansion

    Total sales were $463.3 million, up 63.1% from the previous year. Meanwhile, net income rose to $54.0 million, a staggering 414.3% rise. As it continued to strengthen its financial foundation with consistent revenue growth from both its self-mining and cloud-mining operations, BitFuFu reached a noteworthy milestone in 2024.

    One of the company’s highlights was its successful NASDAQ IPO in March, which improved its market position. The second half of the year saw FUFU make a strategic change from an asset-light approach to a hybrid one that included asset ownership through the acquisition of data center infrastructure.

    With 164 MW of secured capacity, BitFuFu is on track to achieve its long-term growth goals. The company has set an ambitious target to increase its capacity by an additional 1 GW by the end of 2026. With about 600,000 registered users by the end of 2024, its cloud-mining division saw significant growth, nearly doubling its user base from the year before.

    Prospects for the Future and Plans for Capacity Extension

    In 2025, BitFuFu expects to see strong revenue growth once again. The business anticipates that its hosting capacity will be between 650 MW and 800 MW, while its mining capacity would be at 33 EH/s.

    By strategically purchasing data centers with competitive power costs, BitFuFu also hopes to improve its cost structure. Operational efficiency will also be improved by the company’s collaboration with Bitmain to purchase up to 80,000 S21 series miners.

    Notable Rises in Bitcoin Holdings and Mining Capacity

    BitFuFu increased its overall mining capacity by 2.6% during the reporting period, reaching 23.5 EH/s on December 31, 2024. With 591,751 registered users, the cloud-mining user base experienced an astounding 94.5% rise.

  • FST Corp. (KBSX) Shares Soar Amid Exciting New Product Launch

    FST Corp. (KBSX) Shares Soar Amid Exciting New Product Launch

    FST Corp. (NASDAQ: KBSX) had a huge rise in its stock value, surging by 15.71% to $2.62 as of the most recent market check. This boost in stock price followed KBSX’s release of a new graphite golf shaft, designed to enhance performance for golfers seeking better distance and accuracy in their fairway woods.

    Using KBS PGW to Revolutionize Golf Equipment

    The KBS PGW (Player’s Graphite Wood) shaft, developed by top steel and graphite golf shaft maker and marketer FST Corp., is designed to maximize performance for players with intermediate swing speeds. Authorized KBS dealers and bespoke shaft fitting shops around the country are presently distributing the recently introduced shaft, which comes in five weight classifications.

    The KBS PGW shaft was created by Kim Braly, Director of Research and Development at FST Corp., and uses cutting-edge engineering to provide greater spin control and higher launch angles. These improvements make it a desirable choice for golfers looking to improve their game since they boost shot accuracy and distance.

    Estimated Market Impact and Anticipated Revenue

    FST Corp. reaffirms its dedication to offering premium golf equipment with the launch of the KBS PGW. A wide range of golfers, from pros to devoted amateurs, are anticipated to be drawn to KBSX’s new shaft due to its capacity to improve shot accuracy and performance. Braly projects that KBS PGW shaft will generate between $1.0 million and $1.5 million in sales in its first year, highlighting the market potential and anticipated uptake by golfers looking for high-end gear.

    Creating a Taipei Flagship Store

    To increase its market presence, FST Corp. built its flagship store in Taipei. The company’s goal of giving golfers the best equipment and experiences has taken a significant turn with the opening of this 5,000-square-foot retail space in the city’s affluent commercial district.

    The new flagship store reflects FST Corp.’s dedication to quality and innovation in the golf industry. From PGA pros to ardent amateurs, the KBS Golf Experience Taipei was designed to cater to a diverse clientele. The business aims to transform client engagement by offering a large assortment of premium golf shafts and individualized fitting services, ensuring that every golfer finds the perfect equipment to enhance their game.

  • Desktop Metal (DM) Stock Soars After Winning Legal Battle

    Desktop Metal (DM) Stock Soars After Winning Legal Battle

    After a court decision in favor of Desktop Metal, Inc. (NYSE: DM) in its continuing legal struggle, the company’s shares saw a sharp increase. The stock of DM had increased by an astounding 91.85% to $4.36 per share as of the most recent market check.

    The Court Gives Desktop Metal the Win

    Desktop Metal won its case against Nano Dimension Ltd. and Nano US I, Inc., its U.S. subsidiary, before the Delaware Court of Chancery. The merger agreement signed by the two organizations on July 2, 2024, was at the heart of the conflict.

    The Court found that Nano Dimension had significantly broken the agreement in a post-trial ruling released on March 24. Furthermore, the Court dismissed all counterclaims made by Nano and granted DM’s request for specific performance.

    Mandates for Merger Completion

    The Court’s order requires Nano Dimension to complete and execute a national security agreement with the Committee on Foreign Investment in the United States (CFIUS) within 48 hours of the decision.

    The final need for the merger to move forward is this agreement. Additionally, Desktop Metal has the right to extend the agreement’s expiration date until the deal is concluded if the merger has not been completed by March 31, 2025.

    Under Rule 54(b) of the Court of Chancery, this decision is immediately appealable to the Delaware Supreme Court as it represents a definitive judgment on the particular performance claims.

    Dedication to Quick Merger Finalization

    In keeping with its promise to stakeholders, workers, and customers, Desktop Metal has reaffirmed its intention to move quickly to complete the transaction. The business is still committed to carrying out its end of the bargain and will keep trying to find a quick solution.

    Implications for Law and Regulation

    Desktop Metal’s legal claims included an official declaration that Nano Dimension had not fulfilled its obligation to obtain regulatory clearance by making reasonable efforts. In order to stop Nano from ending the contract or acting against its end of the bargain, DM also sought an injunction.

  • Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event

    Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event

    According to the most recent check, shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) are seeing a massive spike today, rising 34.78% on the charts to $2.01. A pivotal investor call featuring Dr. Ehab Atallah, a professor of medicine at the Medical College of Wisconsin and the principal investigator of the Actimab-A + CLAG-M combination trial in patients with relapsed or refractory acute myeloid leukemia (r/r AML), was held at the same time as the notable increase.

    Perspectives on Clinical Advancements and Actimab-A

    Dr. Atallah discussed Actimab-A’s clinical development during the event, including long-term survival statistics and strategies for an upcoming Phase 2/3 pivotal study in r/r AML. Trials carried out under Actinium’s cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) were also discussed. The management team of ATNM also explained its recently launched Actimab-A solid tumor program, which aims to increase the use of its targeted radiotherapies.

    Growing Oncology Market Potential

    Three significant multibillion-dollar market prospects for ATNM’s targeted radiotherapies were highlighted in the company’s most recent reports. One of them is Actimab-A, which may be used in a variety of therapeutic scenarios as a mutation-agnostic backbone therapy for myeloid malignancies, such as AML and myelodysplastic syndromes (MDS).

    Another key area of focus is Actimab-A’s potential in treating solid tumors by combining with PD-1 inhibitors such as KEYTRUDA and OPDIVO. Additionally, Actinium is advancing Iomab-ACT as a universal targeted conditioning agent to enhance access to cell and gene therapies and improve patient outcomes.

    Strategic Partnership to Ensure Supply of Actinium-225

    In order to ensure a consistent supply of Actinium-225 (Ac-225), ATNM has signed a supply deal with Eckert & Ziegler, further bolstering its R&D efforts. Actimab-A and other pipeline candidates will continue to be developed in both domestic and foreign clinical trials with the help of this crucial component.

    Actinium continues to lead the way in targeted radiotherapy innovation as Actimab-A advances into pivotal studies for r/r AML in frontline settings under the NCI cooperation. ATNM is positioned as a global leader in meeting important unmet cancer requirements thanks to its fortified supply chain and foray into solid tumor therapies.